Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to Lumos Pharma's Second Quarter 2024 Financial Results and Clinical Programs Update Call. Currently, all participants are in a listen-only mode.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
2. | Lion Point Didric Cederholm | 0 | $0 | 0% | |
3. | ADAR1 Capital Management Daniel Schneeberger | 0 | $0 | 0% | |
4. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 100 | $387 | 0% | |
2. | 0 | $0 | 0% | |
3. | 0 | $0 | 0% | |
4. | 0 | $0 | 0% |